REGENXBIO, Inc. (RGNX)
9.04
+0.29
(+3.31%)
USD |
NASDAQ |
Feb 27, 16:00
9.045
0.00 (0.00%)
After-Hours: 20:00
REGENXBIO Research and Development Expense (TTM) : 203.30M for Sept. 30, 2025
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Sarepta Therapeutics, Inc. | 1.516B |
| BioMarin Pharmaceutical, Inc. | 700.97M |
| Omeros Corp. | 84.14M |
| Ultragenyx Pharmaceutical, Inc. | 714.72M |
| CytomX Therapeutics, Inc. | 61.25M |